@2022 - All Right Reserved. Designed and Developed by PenciDesign

Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

AstraZeneca to supply COVID-19 antibody cocktail to Singapore

by maria
0 comment

SINGAPORE (Reuters) – AstraZeneca said on Friday it will supply Singapore with its COVID-19 antibody cocktail, Evusheld, by the end of the year.

Evusheld can act as another layer of protection, alongside vaccines, for people who are at high risk of COVID-19 infection, according to AstraZeneca’s statement.

The company did not specify how many courses of the treatment would be supplied to the Southeast Asian city-state.

The U.S. Food and Drug Administration on Wednesday authorised the use of Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.

(Reporting by Chen Lin in Singapore; Editing by Ed Davies)

Recent Post